Innovent Biologics (HKSE:01801) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01801 Innovent Biologics Inc HKSE:01801
84 GF Score
Price HK$88.95
GF Value HK$100.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01801
84GF Score
Innovent Biologics Inc HKSE:01801
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innovent Biologics (HKSE:01801) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of HK$88.95 is trading 11.9% below its estimated GF Value™ of HK$100.93. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for HKSE:01801:

  • FFO:
  • GF Value™: HK$100.93 vs. price of HK$88.95 (11.9% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the HKSE:01801 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
84GF Score

Get the complete analysis for HKSE:01801

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$88.95
Price
HK$100.93
GF Value